LIFE INSPIRING IDEAS

Presented By:
Kritika Aneja (04)
Ruchira Calla (11)
Abhishek Kumar (34)
Disha Mehta (45)
OUR VISION….
“As we navigate our business through the
challenging times ahead, we are determined that
we will not lose sight of our commitment to
doing the right thing, not the easy thing. We will
continue to focus on delivering enduring value
for our stakeholders and society through both
what we do and how we do it.”
MISSION….
• “We want AstraZeneca to be valued both
as a source of great medicines and as a
company committed to delivering
business success responsibly.”
CORPORATE OVERVIEW….
 Formed on 6 April 1999 by the re merger of
Swedish Astra AB and British Zeneca Group plc.
 Head office - City of Westminster, London.
 the merger produced one of the world's largest
pharmaceutical companies, employing 66,000 people in
over 100 countries worldwide, , with a growing presence
in emerging markets such as China, Brazil, India and
Russia
 In fiscal year 2010, AstraZeneca reported almost $33.27
billion in sales and $11.5 billion in operating profit.
 impressive portfolio of drugs includes some of the world's
most successful blockbusters like the ubiquitous "purple
pill" heartburn drug Nexium and cholesterol fighter
Crestor
 AstraZeneca had 9 blockbuster drugs in 2010 (Seroquel IR
and Seroquel XR combined brought in $5.302 billion).
 These products generated 75% of the company's revenue in
2010.
• Around 11,600 people work in our R&D organisation and
we have 17 principal R&D centres in eight countries,
including Sweden, the US and the UK
• Major R&D centers are located in India, Sweden, U.K. and
U.S. AstraZeneca has a large R&D centre in Cheshire, U.K.;
this centre acts as one of Zeneca's main hubs.
FINANCIAL OVERVIEW…
 In Q1 of 2010, AstraZeneca reported sales of $8.6 billion,
an increase of 11% from 2008. The company reported net
income for the quarter of $2.9 billion, a 29% growth.

 In Q2 of 2010, AstraZeneca reported sales of $8.18 billion,

an increase of 2.8% from Q2 of 2009. The company
reported net income for the quarter of $2.1 billion, a 22%
growth.

 In Q3 of 2010, AstraZeneca reported sales of $7.89 billion,

a decrease of 2% from Q3 of 2009. The company reported
net income for the quarter of $1.54 billion, a 26% decline
 Sales increased in markets outside the US increased by 7
% which included a 14 percent increase in Emerging
Markets.

 The company also saw strong double-digit sales growth

for Crestor, Symbicort and Seroquel XR.

 In Q4 of 2010, AstraZeneca reported sales of $8.617

billion, a decrease of 4% from Q4 of 2009. The company
reported net income for the quarter of $1.632 billion, a
4.8% increase.
Business Segments…
TOP BRANDS GROWTH….
STRATEGY….
• Focused - continue to be selective about those
areas of the industry in which we choose to
compete, targeting those product categories
where medical innovation or brand equity
-continues to enable us to make acceptable levels
of returns on our investments.
• Integrated - the best way to capture value within
this industry is to span the full value chain of
discovery, development and commercialisation.
 Innovation-driven -technology base will
continue to deliver innovative products that
patients will want and for which payers will pay

 Global - ability efficiently and effectively to meet

healthcare needs in both Established and
Emerging Markets.
 R&D productivity

Regulatory
Pricing CHALLENGE Requirements
pressure
S

Competition
SWOT ANALYSIS
• STRENGTH • WEAKNESS

Ten products. gambles.

Failures of
The global reach of
the company. crisis.
Drug shortage
Strong growth

Current
pharmaceutical
breakthrough
industry.
Potential to create

Pricing pressures.
Innovative drugs.

Concerns on
Recent success.
various things
• OPPORTUNITIES • THREATS
Future PRIORITIES….